Introduction#
Physitrack PLC has reached an important milestone by achieving profitability for the first time in its Q1 2026 earnings report. The company reported a net profit of EUR 58,000, a significant improvement from a loss of EUR 376,000 in the same quarter last year.
Company Performance#
This quarter marked a pivotal moment for Physitrack, driven by strategic restructuring and a focus on subscription-based revenue, which now makes up 96% of its total income. Despite losing a major customer in the UK, the Lifecare division saw a 6% year-on-year revenue increase. Overall, the company reported revenues of EUR 3.2 million, reflecting a 3% growth compared to Q1 2025.
Financial Highlights#
- Revenue: EUR 3.2 million, up 3% year-on-year.
- Net Profit: EUR 58,000, a turnaround from a net loss of EUR 376,000 in Q1 2025.
- Adjusted EBITDA: EUR 1.1 million, with a 34% margin.
- Free Cash Flow: Positive at EUR 0.1 million.
- Available Liquidity: EUR 2 million at the end of the quarter.
Outlook & Guidance#
Looking ahead, Physitrack remains optimistic about its future. Projections for fiscal years 2026 and 2027 indicate continued growth in earnings per share (EPS) and revenue. The anticipated launch of the Remote Therapeutic Monitoring (RTM) platform in Q2 2026 is expected to significantly boost revenue, potentially increasing monthly license revenue by 3 to 10 times.
Executive Commentary#
CEO Henrik Molin emphasized the importance of this profitability milestone, stating, "Achieving profitability is a significant milestone for Physitrack, reflecting our strategic focus and operational efficiency. The upcoming launch of our RTM platform will further solidify our market position and drive future growth."
Risks and Challenges#
Despite the positive results, Physitrack faces challenges, including potential currency fluctuations that could impact revenue growth. The market's response to the RTM platform launch will also be crucial for future revenue projections.